OX40L Inhibition Suppresses KLH‐driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof‐of‐Pharmacology for KY1005

The safety, tolerability, immunogenicity, and pharmacokinetic (PK) profile of an anti‐OX40L monoclonal antibody (KY1005, currently amlitelimab) were evaluated. Pharmacodynamic (PD) effects were explored using keyhole limpet hemocyanin (KLH) and tetanus toxoid (TT) immunizations. Sixty‐four healthy m...

Descripción completa

Detalles Bibliográficos
Autores principales: Saghari, Mahdi, Gal, Pim, Gilbert, Sally, Yateman, Martin, Porter‐Brown, Ben, Brennan, Nuala, Quaratino, Sonia, Wilson, Rosamund, Grievink, Hendrika W., Klaassen, Erica S., Bergmann, Kirsten R., Burggraaf, Jacobus, van Doorn, Martijn B. A., Powell, John, Moerland, Matthijs, Rissmann, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314635/
https://www.ncbi.nlm.nih.gov/pubmed/35092305
http://dx.doi.org/10.1002/cpt.2539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314635/
https://www.ncbi.nlm.nih.gov/pubmed/35092305
http://dx.doi.org/10.1002/cpt.2539

Ejemplares similares